|
Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. |
|
|
No Relationships to Disclose |
|
|
Employment - AgNovos (I); Qiagen (I); Regulatory and Quality Solutions (I) |
|
|
|
Stock and Other Ownership Interests - COTA |
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; IQVIA |
|
|
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie |
Consulting or Advisory Role - Deciphera; Okava Pharmaceuticals; Tactical Therapeutics; TYME |
|
|
Employment - COTA Healthcare |
Stock and Other Ownership Interests - Abbvie; COTA Healthcare; Johnson & Johnson; UnitedHealthcare |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Syapse |
Travel, Accommodations, Expenses - Syapse |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Employment - Concerto HealthAI |
Stock and Other Ownership Interests - Ampio Pharmaceuticals (I); Johnson & Johnson |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst) |
|
|
|
|
Honoraria - Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - Advi; Boehringer Ingelheim; Bristol-Myers Squibb; New Century Health |
Research Funding - Side-Out Foundation (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Syapse |
|
|
No Relationships to Disclose |
|
|
Employment - Concerto HealthAI |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HERON (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst) |
|
|
No Relationships to Disclose |